Breaks Categories: Stock Spotlights

ThursdayMay 15, 2025 3:35 pm

BioMedNewsBreaks — Adageis’ Fintech Platform Drives Smarter, More Profitable Healthcare

Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based Care Engine and Patented Risk Engine, identify care gaps and high-risk patients, enabling earlier interventions that enhance both clinical and financial performance. By developing targeted solutions, with a focus on smaller and independent practices, Adageis…

Continue Reading

ThursdayMay 15, 2025 2:47 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch platform for managing chronic pain. The company also deepened its collaboration with Kindeva Drug Delivery through an amended agreement focused on the development of Aversa(TM) Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl…

Continue Reading

FridayMay 09, 2025 2:54 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a multimodal mechanism of action, which includes direct killing of the tumors and robust activation of antitumor immune responses, may revolutionize the way we approach cancer treatments,” said a Calidi spokesman. “We are excited to have shown…

Continue Reading

ThursdayMay 08, 2025 3:37 pm

BioMedNewsBreaks — Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

Adageis, a healthcare technology company, is transforming how providers manage insurance payments with its AI-driven software platform, designed to enhance transparency, ensure reimbursement, and support the shift to value-based care. By offering real-time insights into expected payments, identifying reimbursement gaps, and evaluating performance, Adageis empowers clinics—especially smaller or new practices—to optimize revenue, negotiate better insurance contracts, and make informed financial decisions. The platform helps providers navigate complex insurance arrangements while improving profitability, quality, and a focus on patient care. With growing interest in the healthcare technology sector, Adageis stands out as a promising investment opportunity. To view the full article,…

Continue Reading

TuesdayApr 29, 2025 12:41 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM)—which uses synthetic hypericin activated by safe visible light—offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision. With patient enrollment underway and interim analysis expected in early 2026, the study is designed to potentially meet the stringent requirements of regulatory agencies in order to strengthen the case for HyBryte(TM) as a commercially available…

Continue Reading

TuesdayApr 29, 2025 11:25 am

BioMedNewsBreaks — Adageis Is Reshaping Patient Care Through Smart Tech

Adageis is revolutionizing healthcare with its flexible, AI-centric software solutions and ProActive Care Platform, built to eliminate administrative burdens and enable providers to focus on patients. With simplicity core to its design, the platform empowers healthcare organizations by identifying missed revenue opportunities from insurers and guiding providers to secure rightful payments. Using predictive analytics through its Patented Risk Engine (“PRE”), Adageis enhances steady cash flow by forecasting incentive payments and factoring receivables. The platform seamlessly integrates with over 90 electronic health record systems, minimizing disruption and easing the shift to value-based care. As the healthcare sector continues in this trend, Adageis…

Continue Reading

FridayApr 11, 2025 3:30 pm

BioMedNewsBreaks — Adageis Brings Power of AI to the Frontlines of Healthcare

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine (“PRE”) enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization. With streamlined onboarding, projected growth and funding, Adageis is poised for significant expansion in the healthcare technology space, offering investors a compelling opportunity to participate in the evolving $19.27 billion healthcare AI market. To…

Continue Reading

FridayApr 04, 2025 3:38 pm

BioMedNewsBreaks — Adageis Positioned to Scale Impact in Health Technology Landscape

Adageis is a forward-thinking healthcare technology company that is transforming patient care with AI-driven software solutions. The company recently secured $2 million in seed financing and plans to utilize the funding to support upgrades to its backend infrastructure, expand Electronic Health Record (“EHR”) system connectivity, and increase sales efforts to promote rapid growth. Its flagship ProActive Care Platform assists healthcare providers in the transition to value-based care, improving patient focus, reducing costs, and increasing reimbursements. Adageis’ technology seamlessly integrates with over 90 EHR systems, enabling smooth implementation without disrupting workflows. By leveraging AI, the company simplifies insurance complexities and supports the…

Continue Reading

TuesdayMar 25, 2025 2:13 pm

BioMedNewsBreaks — Adageis Is Bringing AI to the Forefront of Value-Based Care

Adageis, a leading healthcare technology company, is at the forefront of an industry shift as providers increasingly prioritize specific, high-impact artificial intelligence (“AI”) applications that enhance patient care and financial performance. The company was featured in a recent article that discussed its innovative AI-driven solutions through its ProActive Care Platform, which offers practical applications that directly impact revenue generation and patient care. Adageis’ AI solutions stand distinct in providing key competencies in several areas including risk identification and early intervention, revenue tracking and forecasting, clinical decision support, administrative task automation, and continuous patient monitoring. Adageis’ platform demonstrates how AI can…

Continue Reading

FridayMar 21, 2025 2:31 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The company’s approach includes a systemic platform using extracellular enveloped viruses and an intratumoral platform utilizing stem cells to protect the therapy from the body’s immune system during administration. Calidi’s pipeline includes promising therapies such as RTNova,…

Continue Reading